American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy

Brian J. Davis, Eric M. Horwitz, W. Robert Lee, Juanita M. Crook, Richard G. Stock, Gregory S. Merrick, Wayne M. Butler, Peter D. Grimm, Nelson N. Stone, Louis Potters, Anthony L. Zietman, Michael J. Zelefsky

Research output: Contribution to journalArticle

274 Citations (Scopus)

Abstract

Purpose: To provide updated American Brachytherapy Society (ABS) guidelines for transrectal ultrasound-guided transperineal interstitial permanent prostate brachytherapy (PPB). Methods and Materials: The ABS formed a committee of brachytherapists and researchers experienced in the clinical practice of PPB to formulate updated guidelines for this technique. Sources of input for these guidelines included prior published guidelines, clinical trials, published literature, andexperience of the committee. The recommendations of the committee were reviewed and approved by the Board of Directors of the ABS. Results: Patients with high probability of organ-confined disease or limited extraprostatic extension are considered appropriate candidates for PPB monotherapy. Low-risk patients may be treated with PPB alone without the need for supplemental external beam radiotherapy. High-risk patients should receive supplemental external beam radiotherapy if PPB is used. Intermediate-risk patients should be considered on an individual case basis. Intermediate-risk patients with favorable features may appropriately be treated with PPB monotherapy but results from confirmatory clinical trials are pending. Computed tomography-based postimplant dosimetry performed within 60 days of the implant is considered essential for maintenance of a satisfactory quality assurance program. Postimplant computed tomography-magnetic resonance image fusion is viewed as useful, but not mandatory. Conclusions: Updated guidelines for patient selection, workup, treatment, postimplant dosimetry, and followup are provided. These recommendations are intended to be advisory in nature withthe ultimate responsibility for the care of the patients resting with the treating physicians.

Original languageEnglish (US)
Pages (from-to)6-19
Number of pages14
JournalBrachytherapy
Volume11
Issue number1
DOIs
StatePublished - Jan 2012

Fingerprint

Brachytherapy
Prostate
Guidelines
Radiotherapy
Tomography
Clinical Trials
Patient Selection
Patient Care
Magnetic Resonance Spectroscopy
Research Personnel
Physicians

Keywords

  • Brachytherapy
  • Dosimetry
  • Guideline
  • Interstitial
  • Prostate cancer
  • Quality assurance
  • Radiation therapy
  • Radiotherapy
  • Safety
  • Standard

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Davis, B. J., Horwitz, E. M., Lee, W. R., Crook, J. M., Stock, R. G., Merrick, G. S., ... Zelefsky, M. J. (2012). American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. Brachytherapy, 11(1), 6-19. https://doi.org/10.1016/j.brachy.2011.07.005

American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. / Davis, Brian J.; Horwitz, Eric M.; Lee, W. Robert; Crook, Juanita M.; Stock, Richard G.; Merrick, Gregory S.; Butler, Wayne M.; Grimm, Peter D.; Stone, Nelson N.; Potters, Louis; Zietman, Anthony L.; Zelefsky, Michael J.

In: Brachytherapy, Vol. 11, No. 1, 01.2012, p. 6-19.

Research output: Contribution to journalArticle

Davis, BJ, Horwitz, EM, Lee, WR, Crook, JM, Stock, RG, Merrick, GS, Butler, WM, Grimm, PD, Stone, NN, Potters, L, Zietman, AL & Zelefsky, MJ 2012, 'American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy', Brachytherapy, vol. 11, no. 1, pp. 6-19. https://doi.org/10.1016/j.brachy.2011.07.005
Davis, Brian J. ; Horwitz, Eric M. ; Lee, W. Robert ; Crook, Juanita M. ; Stock, Richard G. ; Merrick, Gregory S. ; Butler, Wayne M. ; Grimm, Peter D. ; Stone, Nelson N. ; Potters, Louis ; Zietman, Anthony L. ; Zelefsky, Michael J. / American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. In: Brachytherapy. 2012 ; Vol. 11, No. 1. pp. 6-19.
@article{58c163c1562147d2a03eb60b79b9bb59,
title = "American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy",
abstract = "Purpose: To provide updated American Brachytherapy Society (ABS) guidelines for transrectal ultrasound-guided transperineal interstitial permanent prostate brachytherapy (PPB). Methods and Materials: The ABS formed a committee of brachytherapists and researchers experienced in the clinical practice of PPB to formulate updated guidelines for this technique. Sources of input for these guidelines included prior published guidelines, clinical trials, published literature, andexperience of the committee. The recommendations of the committee were reviewed and approved by the Board of Directors of the ABS. Results: Patients with high probability of organ-confined disease or limited extraprostatic extension are considered appropriate candidates for PPB monotherapy. Low-risk patients may be treated with PPB alone without the need for supplemental external beam radiotherapy. High-risk patients should receive supplemental external beam radiotherapy if PPB is used. Intermediate-risk patients should be considered on an individual case basis. Intermediate-risk patients with favorable features may appropriately be treated with PPB monotherapy but results from confirmatory clinical trials are pending. Computed tomography-based postimplant dosimetry performed within 60 days of the implant is considered essential for maintenance of a satisfactory quality assurance program. Postimplant computed tomography-magnetic resonance image fusion is viewed as useful, but not mandatory. Conclusions: Updated guidelines for patient selection, workup, treatment, postimplant dosimetry, and followup are provided. These recommendations are intended to be advisory in nature withthe ultimate responsibility for the care of the patients resting with the treating physicians.",
keywords = "Brachytherapy, Dosimetry, Guideline, Interstitial, Prostate cancer, Quality assurance, Radiation therapy, Radiotherapy, Safety, Standard",
author = "Davis, {Brian J.} and Horwitz, {Eric M.} and Lee, {W. Robert} and Crook, {Juanita M.} and Stock, {Richard G.} and Merrick, {Gregory S.} and Butler, {Wayne M.} and Grimm, {Peter D.} and Stone, {Nelson N.} and Louis Potters and Zietman, {Anthony L.} and Zelefsky, {Michael J.}",
year = "2012",
month = "1",
doi = "10.1016/j.brachy.2011.07.005",
language = "English (US)",
volume = "11",
pages = "6--19",
journal = "Brachytherapy",
issn = "1538-4721",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy

AU - Davis, Brian J.

AU - Horwitz, Eric M.

AU - Lee, W. Robert

AU - Crook, Juanita M.

AU - Stock, Richard G.

AU - Merrick, Gregory S.

AU - Butler, Wayne M.

AU - Grimm, Peter D.

AU - Stone, Nelson N.

AU - Potters, Louis

AU - Zietman, Anthony L.

AU - Zelefsky, Michael J.

PY - 2012/1

Y1 - 2012/1

N2 - Purpose: To provide updated American Brachytherapy Society (ABS) guidelines for transrectal ultrasound-guided transperineal interstitial permanent prostate brachytherapy (PPB). Methods and Materials: The ABS formed a committee of brachytherapists and researchers experienced in the clinical practice of PPB to formulate updated guidelines for this technique. Sources of input for these guidelines included prior published guidelines, clinical trials, published literature, andexperience of the committee. The recommendations of the committee were reviewed and approved by the Board of Directors of the ABS. Results: Patients with high probability of organ-confined disease or limited extraprostatic extension are considered appropriate candidates for PPB monotherapy. Low-risk patients may be treated with PPB alone without the need for supplemental external beam radiotherapy. High-risk patients should receive supplemental external beam radiotherapy if PPB is used. Intermediate-risk patients should be considered on an individual case basis. Intermediate-risk patients with favorable features may appropriately be treated with PPB monotherapy but results from confirmatory clinical trials are pending. Computed tomography-based postimplant dosimetry performed within 60 days of the implant is considered essential for maintenance of a satisfactory quality assurance program. Postimplant computed tomography-magnetic resonance image fusion is viewed as useful, but not mandatory. Conclusions: Updated guidelines for patient selection, workup, treatment, postimplant dosimetry, and followup are provided. These recommendations are intended to be advisory in nature withthe ultimate responsibility for the care of the patients resting with the treating physicians.

AB - Purpose: To provide updated American Brachytherapy Society (ABS) guidelines for transrectal ultrasound-guided transperineal interstitial permanent prostate brachytherapy (PPB). Methods and Materials: The ABS formed a committee of brachytherapists and researchers experienced in the clinical practice of PPB to formulate updated guidelines for this technique. Sources of input for these guidelines included prior published guidelines, clinical trials, published literature, andexperience of the committee. The recommendations of the committee were reviewed and approved by the Board of Directors of the ABS. Results: Patients with high probability of organ-confined disease or limited extraprostatic extension are considered appropriate candidates for PPB monotherapy. Low-risk patients may be treated with PPB alone without the need for supplemental external beam radiotherapy. High-risk patients should receive supplemental external beam radiotherapy if PPB is used. Intermediate-risk patients should be considered on an individual case basis. Intermediate-risk patients with favorable features may appropriately be treated with PPB monotherapy but results from confirmatory clinical trials are pending. Computed tomography-based postimplant dosimetry performed within 60 days of the implant is considered essential for maintenance of a satisfactory quality assurance program. Postimplant computed tomography-magnetic resonance image fusion is viewed as useful, but not mandatory. Conclusions: Updated guidelines for patient selection, workup, treatment, postimplant dosimetry, and followup are provided. These recommendations are intended to be advisory in nature withthe ultimate responsibility for the care of the patients resting with the treating physicians.

KW - Brachytherapy

KW - Dosimetry

KW - Guideline

KW - Interstitial

KW - Prostate cancer

KW - Quality assurance

KW - Radiation therapy

KW - Radiotherapy

KW - Safety

KW - Standard

UR - http://www.scopus.com/inward/record.url?scp=84862908703&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862908703&partnerID=8YFLogxK

U2 - 10.1016/j.brachy.2011.07.005

DO - 10.1016/j.brachy.2011.07.005

M3 - Article

C2 - 22265434

AN - SCOPUS:84862908703

VL - 11

SP - 6

EP - 19

JO - Brachytherapy

JF - Brachytherapy

SN - 1538-4721

IS - 1

ER -